The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 28, 2010

Filed:

Apr. 04, 2008
Applicants:

Stefanie Keil, Frankfurt am Main, DE;

Hans Matter, Frankfurt am Main, DE;

Karl Schoenafinger, Alzenau, DE;

Matthias Urmann, Frankfurt am Main, DE;

Maike Glien, Frankfurt am Main, DE;

Wolfgang Wendler, Frankfurt am Main, DE;

Hans-ludwig Schaefer, Frankfurt am Main, DE;

Eugen Falk, Frankfurt am Main, DE;

Inventors:

Stefanie Keil, Frankfurt am Main, DE;

Hans Matter, Frankfurt am Main, DE;

Karl Schoenafinger, Alzenau, DE;

Matthias Urmann, Frankfurt am Main, DE;

Maike Glien, Frankfurt am Main, DE;

Wolfgang Wendler, Frankfurt am Main, DE;

Hans-Ludwig Schaefer, Frankfurt am Main, DE;

Eugen Falk, Frankfurt am Main, DE;

Assignee:

Sanofi-Aventis, Paris, FR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4436 (2006.01); A61K 31/433 (2006.01); C07D 417/12 (2006.01); C07D 285/135 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention comprises N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their physiologically acceptable salts and functional derivatives that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, And the isomers thereof wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.


Find Patent Forward Citations

Loading…